FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jodi Bradley

Research Profile

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Dietmar Seiffert; Beth E Thomas; Jodi D Bradley; Deborah A Munzer; Maureen A Tchinnes; David M Kornhauser; Valerie A Cain; Tsushung Hua; Giora Z Feuerstein; David E Martin; Andrew M Stern
Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
Yuval Blat; Jere E Meredith; Qian Wang; Jodi D Bradley; Lorin A Thompson; Richard E Olson; Andrew M Stern; Dietmar Seiffert
Mutations at the P1' position of Notch1 decrease intracellular domain stability rather than cleavage by gamma-secretase.
Jeffrey T Billheimer; ira dicker; Richard Wynn; Jodi D Bradley; Debra Cromley; Helen E Godonis; Lisa C Grimminger; Bokang He; Cathy J Kieras; Donna L Pedicord; Susan M Spitz; Beth E Thomas; Nina I Zolotarjova; Mary A Gorko; Gregory F Hollis; Robert N Daly; Andrew M Stern; Dietmar Seiffert
Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jodi Bradley (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: Dietmar Seiffert; Beth E Thomas; Jodi D Bradley; Deborah A Munzer; Maureen A Tchinnes; David M Kornhauser; Valerie A Cain; Tsushung Hua; Giora Z Feuerstein; David E Martin; Andrew M Stern
Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
Platelets 2003;14(3):179-87.
2002: Yuval Blat; Jere E Meredith; Qian Wang; Jodi D Bradley; Lorin A Thompson; Richard E Olson; Andrew M Stern; Dietmar Seiffert
Mutations at the P1' position of Notch1 decrease intracellular domain stability rather than cleavage by gamma-secretase.
Biochemical and biophysical research communications 2002;299(4):569-73.
2002: Jeffrey T Billheimer; ira dicker; Richard Wynn; Jodi D Bradley; Debra Cromley; Helen E Godonis; Lisa C Grimminger; Bokang He; Cathy J Kieras; Donna L Pedicord; Susan M Spitz; Beth E Thomas; Nina I Zolotarjova; Mary A Gorko; Gregory F Hollis; Robert N Daly; Andrew M Stern; Dietmar Seiffert
Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.
Blood 2002;99(10):3540-6.
2000: Dietmar Seiffert; Jodi D Bradley; Cynthia M Rominger; David H Rominger; F Yang; Jere E Meredith; Qian Wang; Arthur H Roach; Lorin A Thompson; Susan M Spitz; Jeffrey N Higaki; Shimoga R Prakash; Andrew P Combs; Robert Copeland; Stephen P Arneric; Paul R Hartig; David W Robertson; Barbara Cordell; Andrew M Stern; Richard E Olson; Robert Zaczek
Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors.
The Journal of biological chemistry 2000;275(44):34086-91.